CYP2D6 is the enzyme behind the metabolism of roughly 25% of all prescription drugs — from antidepressants to pain medications to cancer drugs. The *2 allele, defined by the rs16947 variant (a C-to-T change causing an Arg296Cys amino acid substitution¹¹ Arg296Cys amino acid substitution
arginine to cysteine at position 296), is one of the most common CYP2D6 variants worldwide. For decades, it was classified as having "normal function," indistinguishable from the reference *1 allele. But recent research reveals a more nuanced story: this variant subtly reduces CYP2D6 expression through altered mRNA splicing, and its true impact depends heavily on what other variants accompany it on the same chromosome.

The Mechanism

The rs16947 variant alters exon 6 splicing, reducing CYP2D6 expression by at least 2-fold . The amino acid change itself (R296C) may reduce enzyme activity slightly in recombinant expression systems, but the bigger effect comes from regulatory consequences.

This SNP defines the CYP2D6*2 allele, with minor allele frequencies ranging from 17–60% across populations .

The *2 allele (rs16947) is the most frequent CYP2D6 variant in European, African, and Latino populations, though less common in East Asians where *10 predominates .

What complicates matters is that rs16947 doesn't act alone.

It's in high linkage disequilibrium with an enhancer SNP (rs5758550) located over 100 kb downstream .

The enhancer SNP increases CYP2D6 expression 2-fold, while rs16947 reduces it by 0.5-fold; haplotypes containing both variants show near-normal activity . This means that a person with two copies of the A allele at rs16947 could have anywhere from reduced to increased enzyme activity depending on the larger haplotype context — something standard genotyping panels often miss.

The Evidence

The landmark discovery came from a 2014 study²² The landmark discovery came from a 2014 study
Wang et al. Common CYP2D6 polymorphisms affecting alternative splicing and transcription. Human Molecular Genetics, 2014 that used allelic expression analysis in human liver samples.

In a pediatric cohort of 164 individuals, rs16947 alone was associated with reduced CYP2D6 metabolic activity measured by dextromethorphan ratios .

Overall allele frequencies harboring rs16947 and/or the enhancer SNP range from 17% in East Asians to 67% in Africans .

A 2019 follow-up study³³ A 2019 follow-up study
Ray et al. CYP2D6 haplotypes with enhancer SNP rs5758550 and rs16947. Pharmacogenetics and Genomics, 2019 tested the haplotype-phenotype relationship in 122 human liver microsomes.

Haplotypes containing both rs5758550 and rs16947 convey normal or slightly increased enzyme activity , supporting the idea that CYP2D6 enzyme function depends on the full haplotype, not single variants in isolation.

Despite this mechanistic evidence,

CPIC currently classifies CYP2D6*2 as having normal function , assigning it an activity score of 1.0 — the same as the reference *1 allele. This classification drives dosing guidelines for dozens of drugs, but may oversimplify for individuals whose *2 allele lacks the compensatory enhancer variant.

Practical Implications

If your 23andMe report shows the A allele at rs16947, you carry at least one copy of CYP2D6*2.

Between 43–67% of individuals have two normal-function alleles (*1 or *2) or one normal plus one decreased-function allele, resulting in normal metabolizer status . However, there is large variability in drug response within individuals genotyped as normal metabolizers, and the causes of this variation are unknown

— the *2/*enhancer haplotype interaction is a leading candidate explanation.

CYP2D6 is responsible for metabolizing many commonly prescribed drugs including antidepressants, antipsychotics, analgesics, and beta-blockers .

Pharmacogenomic clinical guidelines for at least 48 CYP2D6-substrate drugs have been developed by CPIC and other consortia. For CYP2D6*2 specifically, current guidelines treat it as normal-function and don't recommend dose adjustments. But if you experience unexpected side effects or lack of efficacy with a CYP2D6-substrate drug, the nuanced function of your *2 allele — especially if not accompanied by the enhancer — could be relevant.

The challenge is that consumer genetic tests like 23andMe typically only report rs16947 itself, not the distant enhancer SNP or the full haplotype structure. Without phased haplotype information, knowing you have *2 tells you less than it should. Clinical pharmacogenetic testing that includes copy number analysis and structural variant detection provides a more complete picture.

Interactions

The rs16947 variant interacts significantly with rs5758550 (enhancer SNP). Individuals who carry rs16947 (A allele) on a haplotype that also has rs5758550 (G allele) tend to have near-normal or slightly elevated CYP2D6 activity. Those with rs16947 but without the enhancer may have moderately reduced activity. This is a case where compound genotyping across a >100 kb span matters more than the single-SNP result.

Additionally, rs16947 defines several star alleles beyond *2, including *29, *17, *35, and others that carry additional functional variants. The *41 allele contains both rs16947 and the splicing-defect variant rs28371725, resulting in clearly reduced function. Because rs16947 is so common and appears in many haplotype backgrounds, interpreting it requires knowing what else is present on that chromosome.

For compound heterozygotes — individuals with one *2 allele and one reduced/no-function allele like *4, *5, or *10 — the impact depends on whether the *2 carries the enhancer. A *2 (with enhancer) plus *4 diplotype might behave like a normal metabolizer, while *2 (without enhancer) plus *4 could trend toward intermediate metabolism.

Before your body can build the long-chain omega-3s and omega-6s it needs for every cell membrane, every eicosanoid signal, and every synapse, it must pass dietary fatty acids through a molecular gateway: delta-6 desaturase¹¹ delta-6 desaturase
FADS2 (fatty acid desaturase 2) encodes delta-6 desaturase, the enzyme that inserts a double bond at the Δ6 position in both the omega-3 and omega-6 pathways. rs174572, an intronic variant in FADS2, alters how efficiently this gateway works. The T allele is associated with reduced desaturase activity and measurably lower circulating EPA — the omega-3 that drives anti-inflammatory eicosanoid production, platelet function, and cardiovascular protection.

The Mechanism

Delta-6 desaturase catalyzes the first and rate-limiting step in two parallel pathways: - Omega-6: linoleic acid (LA, 18:2n-6) → gamma-linolenic acid (GLA, 18:3n-6) - Omega-3: alpha-linolenic acid (ALA, 18:3n-3) → stearidonic acid (SDA, 18:4n-3)

Without adequate D6D activity, dietary precursors accumulate (higher LA and ALA in plasma) while downstream products (GLA, stearidonic acid, and ultimately EPA, DHA, and AA) remain low. rs174572 sits in intron 1 of FADS2, and — consistent with findings in the broader FADS locus — likely affects FADS2 promoter methylation and transcriptional activity²² FADS2 promoter methylation and transcriptional activity
Allele-specific methylation at FADS cluster intronic and promoter CpG sites has been confirmed in multiple tissues; intronic SNPs in high LD with the cluster tag this regulatory effect. T allele carriers produce less FADS2 enzyme, throttling both pathways simultaneously.

The Evidence

The most direct evidence comes from a genome-wide fatty acid study of 1,144 European adolescents in the HELENA cohort³³ genome-wide fatty acid study of 1,144 European adolescents in the HELENA cohort
Bokor et al. J Lipid Res 2010; 51:2325–2333; 13 FADS SNPs genotyped across 9 European countries. Carriers of the minor T allele at rs174572 showed significantly higher plasma LA (p=0.0009), higher ALA (p=0.0002), and higher DGLA — precursors that had not been converted downstream. Simultaneously, arachidonic acid was lower (p<1×10⁻⁶) and EPA was substantially lower (p=4.2×10⁻⁶). The D5D activity index (which reflects the overall efficiency of the cascade) fell from 3.70 in CC homozygotes to 3.06 in CT heterozygotes and 2.60 in TT homozygotes (p=6.1×10⁻³¹) — one of the strongest genotype-to-enzyme associations observed in the FADS gene cluster.

A 2024 scoping review of 40 studies⁴⁴ 2024 scoping review of 40 studies
Loukil, Mutch & Plourde, Genes Nutr 2024; DOI: 10.1186/s12263-024-00747-4 confirmed that minor allele carriers of rs174572 have lower circulating EPA, placing this SNP among the FADS variants with documented EPA-specific associations.

The cardiovascular relevance of FADS-driven PUFA imbalances is documented in a study of 876 subjects⁵⁵ study of 876 subjects
Martinelli et al. Am J Clin Nutr 2008 where a high AA-to-LA ratio (reflecting high D5D activity, the opposite of what T allele carriers have) independently predicted CRP elevation and coronary artery disease risk (OR ~2.55). For T allele carriers, the clinical concern is the mirror image: chronically low EPA results in reduced production of anti-inflammatory eicosanoids (prostaglandin E3, thromboxane A3) and inadequate cardiovascular protection from omega-3 signaling — without the genetic test, this functional deficiency is invisible.

Practical Actions

Because D6D activity is the first committed step in PUFA synthesis, T allele carriers cannot compensate by eating more flaxseed, chia, or walnuts. Those sources supply ALA, which still must pass through the impaired D6D gate before becoming stearidonic acid, EPA, or DHA. The only reliable route to adequate EPA is preformed EPA from marine or algae sources that bypass the conversion step entirely.

For TT homozygotes — the most affected genotype — supplementation with 2–4 g combined EPA+DHA daily from concentrated fish oil or algae-based sources is the most targeted approach. For CT heterozygotes, 1–2 g daily represents a reasonable starting point. The omega-3 index (erythrocyte EPA+DHA percentage) provides a direct, individualized measure of whether supplementation is achieving adequate tissue levels.

Interactions

rs174572 is located near rs174547, rs174546, rs174537, rs174575, and rs174589 in the FADS gene cluster on chromosome 11q12.2. These variants co-segregate as haplotype blocks, and carrying T alleles across multiple FADS cluster SNPs compounds the reduction in overall PUFA conversion capacity. The functional impact is therefore greater in individuals who carry risk alleles at both FADS2 (rs174572, D6D — the first step) and FADS1 (rs174537 or rs174547, D5D — the downstream step), as both desaturase steps become rate-limited simultaneously. This combination represents a proposal for a compound action (see harvesting notes).

Every neurotransmitter that regulates sleep — serotonin, melatonin, GABA, and dopamine — depends on the same molecular key: pyridoxal 5'-phosphate (PLP), the active form of vitamin B6. Dietary vitamin B6 (pyridoxine or pyridoxamine from food and most supplements) is not active on its own. Before your brain can use it, the enzyme PNPO¹¹ PNPO
Pyridoxamine 5'-phosphate oxidase — catalyzes the final oxidation step converting PNP and PMP to PLP, the biologically active cofactor form of vitamin B6 (pyridoxamine 5'-phosphate oxidase) must convert it to PLP. The rs17679445 Arg116Gln variant substitutes a glutamine for arginine at position 116 of PNPO, reducing the enzyme's catalytic efficiency and thereby limiting the supply of PLP to the neurotransmitter-synthesizing enzymes that depend on it.

The Mechanism

PNPO sits at the final step of B6 activation. It oxidizes both pyridoxine 5'-phosphate (PNP) and pyridoxamine 5'-phosphate (PMP) into PLP. Without adequate PLP, multiple downstream enzymes falter simultaneously. The most sleep-relevant are:

• Aromatic amino acid decarboxylase (AADC/DDC) — converts 5-HTP to serotonin and L-DOPA to dopamine; requires PLP as essential cofactor. A 2022 structural study²² 2022 structural study
  Al Mughram MH et al. Elucidating the Interaction between Pyridoxine 5'-Phosphate Oxidase and Dopa Decarboxylase. Int J Mol Sci, 2022 showed that PNPO physically binds to AADC and directly delivers PLP to it — making PNPO's efficiency a rate-limiting step for serotonin and dopamine production.
• Glutamic acid decarboxylase (GAD) — converts glutamate to GABA, the brain's primary inhibitory neurotransmitter; PLP-dependent. Reduced GAD activity is the central mechanism in PNPO-deficiency epilepsy.
• Tryptophan aminotransferase — a PLP-dependent enzyme in the melatonin synthesis pathway. Lower PLP availability reduces pineal melatonin output, as demonstrated in B6-deficient animal models³³ B6-deficient animal models
  Dakshinamurti K et al. Neuroendocrinology of pyridoxine deficiency. Neurosci Biobehav Rev, 1988 where B6 deficiency reduced both hypothalamic serotonin and pineal melatonin.

The Arg116Gln substitution replaces a positively charged arginine (which stabilizes the enzyme's active site) with a neutral glutamine. While this does not abolish enzyme function (unlike homozygous loss-of-function mutations that cause neonatal epilepsy), it reduces catalytic efficiency — producing a partial, dose-dependent reduction in PLP output that is particularly relevant in carriers who consume standard (non-activated) vitamin B6 supplements or have modest dietary B6 intake.

The Evidence

The variant's association with insomnia was identified in the landmark Jansen et al. 2019⁴⁴ Jansen et al. 2019
Jansen PR et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nature Genetics, 2019 genome-wide association study of 1,331,010 individuals, which identified 202 insomnia risk loci implicating 956 genes. The PNPO locus on chromosome 17 was among the hits. While GWAS identifies association rather than causation, the biological plausibility is high: the entire neurotransmitter cascade governing sleep initiation and maintenance — serotonin → melatonin, GABA synthesis, dopamine signaling — converges on PLP as a shared cofactor.

A comprehensive 2019 review⁵⁵ comprehensive 2019 review
Wilson MP et al. Disorders affecting vitamin B6 metabolism. J Inherit Metab Dis, 2019 of vitamin B6 metabolism disorders confirmed that PLP (produced by PNPO) is the sole active cofactor form capable of driving neurotransmitter synthesis reactions in the central nervous system.

Supporting the sleep-B6 link at a clinical level, two controlled trials showed that vitamin B6 supplementation affects sleep architecture. An RCT by Ebben et al. (2002)⁶⁶ RCT by Ebben et al. (2002)
Ebben M et al. Effects of pyridoxine on dreaming: a preliminary study. Perceptual and Motor Skills, 2002 found that 250 mg pyridoxine before sleep significantly enhanced dream salience (vividness, emotionality, color) compared to placebo over 5 nights, hypothesizing enhanced B6-to-serotonin conversion as the mechanism. A larger RCT by Aspy et al. (2018)⁷⁷ RCT by Aspy et al. (2018)
Aspy DJ et al. Effects of Vitamin B6 (Pyridoxine) and a B Complex Preparation on Dreaming and Sleep. Perceptual and Motor Skills, 2018 replicated increased dream recall in 100 participants taking 240 mg pyridoxine.

ClinVar classifies the A allele (Arg116Gln) as benign for PNPO-deficiency epilepsy — consistent with the protein retaining substantial function. The sleep association reflects a subtler, quantitative reduction in PLP production relevant at the population level rather than a clinical disease state.

Practical Actions

The key insight for Arg116Gln carriers is the bypass strategy: while standard vitamin B6 supplements contain pyridoxine or pyridoxamine that require PNPO to activate, pyridoxal-5-phosphate (P5P) is the already-activated form that enters cells and reaches neurotransmitter- synthesizing enzymes without needing PNPO conversion. Using P5P directly circumvents the enzymatic bottleneck at the Arg116Gln substitution.

Homozygous A carriers (Arg116Gln/Arg116Gln) represent the extreme of impaired conversion and should particularly consider P5P supplementation. Heterozygous AG carriers have an intermediate phenotype with partial reduction in conversion efficiency.

Interactions

PNPO Arg116Gln is most likely to be clinically relevant in the context of other factors that further stress PLP availability: low dietary B6 intake, high protein intake (which increases B6 demand for amino acid metabolism), oral contraceptive use (which depletes B6), or genetic variants in B6 transport or metabolism. No specific gene-gene interaction studies with rs17679445 have been published, but carriers of both PNPO Arg116Gln and variants affecting tryptophan metabolism (e.g., MTHFR, which shares PLP-dependent enzymes in the one-carbon cycle) may experience compounded effects on neurotransmitter synthesis.

PPARα¹¹ PPARα
Peroxisome Proliferator-Activated Receptor Alpha — a nuclear receptor transcription factor that acts as the master regulator of fatty acid oxidation, lipoprotein metabolism, and energy substrate utilization during fasting and exercise is one of the most important lipid-sensing proteins in the human body. It responds to dietary fats, exercise, and fasting by switching on a gene expression program that burns fat for energy and clears lipids from the bloodstream. The Leu162Val missense variant (rs1800206) substitutes valine for leucine at position 162 of the PPARα protein, subtly altering the receptor's transcriptional behavior — with consequences that depend strongly on what you eat.

The Mechanism

Position 162 sits in the DNA-binding domain²² DNA-binding domain
The DNA-binding domain of PPARα recognizes specific peroxisome proliferator response elements (PPREs) in gene promoters and, once ligand-activated, drives transcription of target genes involved in fatty acid oxidation, lipoprotein lipase production, and apolipoprotein synthesis of the PPARα protein. In vitro experiments show that the Val162 variant (G allele) produces consistently lower transcriptional activation³³ consistently lower transcriptional activation
Rudkowska et al. 2009 (PPAR Res) showed V162 cells had significantly lower PPARα and APOA1 expression after EPA and DHA treatment in HepG2 hepatoma cells than L162 wild-type cells than the common Leu162 form when stimulated with omega-3 fatty acids. This blunted responsiveness translates into downstream effects: lower lipoprotein lipase (LPL) activity, reduced clearance of triglyceride-rich lipoproteins, and less efficient production of ApoA-I (a key structural protein in HDL particles).

The paradox of this variant is that despite reduced intrinsic activity, V162 carriers do not uniformly show worse lipid profiles — the consequences depend critically on dietary fat composition. When dietary polyunsaturated fatty acid (PUFA) intake is low, the variant exposes its metabolic vulnerability; when PUFA intake is adequate (≥8% of energy), the phenotype largely normalizes.

The Evidence

The largest genetic epidemiology evidence comes from the Framingham Offspring Study⁴⁴ Framingham Offspring Study
Tai ES et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol, 2002, which genotyped 2,373 participants (V162 allele frequency 6.9%) and found significant associations in men: higher LDL cholesterol (P=0.0004), higher total cholesterol (P=0.0012), higher ApoB (P=0.009), and elevated ApoC-III concentrations — all pointing toward impaired clearance of atherogenic lipoproteins.

The gene-diet interaction was characterized elegantly in the Framingham Heart Study dietary analysis⁵⁵ Framingham Heart Study dietary analysis
Tai ES et al. Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr, 2005, where V162 carriers on low PUFA diets (<6% of energy) showed approximately 28% higher plasma triglycerides than L162 homozygotes (P<0.01), while V162 carriers on high-PUFA diets (>8% of energy) showed 4% lower triglycerides. The interaction was dose-dependent and highly significant (P=0.031 for triglycerides, P<0.001 for ApoC-III), confirming that dietary fat composition determines whether this variant is harmful or neutral.

In a cohort of 610 young adults, Robitaille et al.⁶⁶ Robitaille et al.
Robitaille J et al. PPARalpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Med Genet, 2007 found that V allele males had 78% higher serum triglycerides than LL homozygotes (208 vs 116 mg/dL, P=0.004) and significantly lower HDL cholesterol (34 vs 42 mg/dL, P=0.001). The variant also predicted an unusual response to exercise training: V allele males actually increased subcutaneous fat in the untrained limb during unilateral resistance training, while LL males reduced fat. Women showed no effect — suggesting the variant's lipid impact is sex-specific.

At the molecular level, two complementary studies by Rudkowska and colleagues⁷⁷ two complementary studies by Rudkowska and colleagues
Rudkowska I et al. Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPARalpha L162V polymorphism. Genes Nutr, 2009 confirmed that V162 carriers show significantly blunted PPARα and ApoA-I gene expression in response to DHA supplementation — meaning the mechanism for HDL generation is impaired. A paired in vivo/in vitro study (PMID 19937854)⁸⁸ (PMID 19937854) further showed that n-3 fatty acid-induced LPL activity increase was roughly halved in V162 carriers (6.6% vs 14.4%), reducing their capacity to clear triglycerides from the blood.

In the STOP-NIDDM trial⁹⁹ STOP-NIDDM trial
Andrulionyte L et al. PPARA gene polymorphisms influence conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes, 2007, the G (Val162) allele increased the risk of progressing from impaired glucose tolerance to overt type 2 diabetes by 1.9-fold (95% CI 1.05–3.58) in the placebo group among 767 participants, with associated elevations in plasma glucose and insulin — likely reflecting the impaired fatty acid oxidation and lipotoxicity consequences of reduced PPARα activity.

There is also an exercise context: a 12-week aerobic training intervention in 168 women (PMID 31319591)¹⁰¹⁰ (PMID 31319591) found that CG genotype carriers showed a decrease in HDL cholesterol after the program, in contrast to the expected improvements in CC carriers — consistent with the reduced PPARα-driven APOA1 response documented in molecular studies.

Practical Actions

The core insight for V162 allele carriers is that dietary PUFA intake is the primary modifiable lever. The gene-diet interaction is one of the cleaner pharmacogenomic effects in nutritional genomics: omega-3 fatty acids act as direct PPARα ligands and should theoretically be most helpful, yet the V162 variant blunts exactly this response. At the same time, the evidence from the fibrate pharmacogenomics literature shows paradoxical benefit — V162 carriers showed dramatically better HDL response to gemfibrozil (a fibrate that directly activates PPARα), suggesting that at sufficiently high levels of PPARα stimulation, the reduced-activity receptor can still be mobilized.

The practical implication: V162 carriers should monitor lipids proactively, maintain high-quality PUFA intake (even if the response is attenuated, low PUFA unmistakably worsens the phenotype), and be aware that standard aerobic exercise programs may not improve HDL as expected. If pharmacotherapy for lipids becomes necessary, fibrate drugs may show above-average HDL benefit in V162 carriers.

Interactions

This variant is in the same gene as rs4253778 (PPARA intron 7 G/C). The intron 7 variant alters PPARA expression level and muscle fiber composition; Leu162Val alters PPARA protein function. They address distinct molecular mechanisms and are not in high LD with each other, allowing independent contributions. Combined unfavorable alleles (CC at rs4253778 and CG/GG at rs1800206) may compound adverse lipid responses to exercise training — the existing rs4253778 entry already notes this interaction (C allele at rs4253778 combined with Val162 at rs1800206 has been associated with more pronounced adverse lipid changes during training).

PPARD (rs2016520, rs1053049) works in the same fat-oxidation pathway as PPARA. While both nuclear receptors regulate lipid metabolism, their actions are largely independent at the genotype level; no formal interaction studies between rs1800206 and PPARD variants have been published in exercise cohorts. The PPARGC1A Gly482Ser variant (rs8192678) is a PGC-1alpha coactivator that physically interacts with PPARα; combined analysis with rs1800206 has not been studied but represents a plausible compound effect.

Every day your liver makes a protein called CETP¹¹ CETP
Cholesteryl Ester Transfer Protein — an enzyme that shuttles cholesteryl esters from protective HDL particles to LDL and VLDL, effectively draining your HDL of its cargo. The more CETP your liver produces, the lower your HDL cholesterol tends to be. A single nucleotide change in the CETP gene's promoter region — 629 bases upstream of the transcription start site — determines how much CETP your liver produces, and therefore shapes your HDL cholesterol set point from birth.

The Mechanism

The -629 position sits within a Sp1/Sp3 transcription factor binding site²² Sp1/Sp3 transcription factor binding site
Sp1 and Sp3 are zinc-finger proteins that bind GC-rich DNA sequences and regulate transcription — Sp3 commonly acts as a repressor when it outcompetes Sp1 at the same site. The C allele creates a sequence that Sp1 and Sp3 bind poorly. The A allele creates a high-affinity Sp1/Sp3 binding site — and Sp3 at this position acts as a transcriptional repressor, suppressing CETP gene expression by approximately 25%.

Carriers of the A allele therefore have lower circulating CETP protein. Because CETP transfers cholesteryl esters from HDL to LDL and VLDL, less CETP activity means cholesteryl esters accumulate inside HDL particles — raising measured HDL cholesterol. The original mechanistic study by Dachet et al.³³ original mechanistic study by Dachet et al. showed that CC homozygotes had 0.45 μg/mL higher circulating CETP mass than AA homozygotes, and correspondingly lower HDL-C levels, in 536 subjects from the ECTIM study.

The Evidence

The largest and most rigorous study of this variant is the Women's Genome Health Study (WGHS)⁴⁴ Women's Genome Health Study (WGHS)
Ridker et al. 2009; 18,245 initially healthy American women of European ancestry, followed prospectively for ~10 years for cardiovascular events. In this genome-wide analysis, rs1800775 was identified as the single most strongly associated SNP in the entire CETP region for HDL-C. HDL-C was approximately 52 mg/dL in CC carriers, 52 mg/dL in CA carriers, and 54 mg/dL in AA homozygotes. The age-adjusted hazard ratio for myocardial infarction was 0.82 per A allele (P=0.048), though this association was attenuated when HDL-C was included in the model (HR 0.90, P=0.31) — suggesting the cardiovascular effect operates largely through HDL.

A 2015 resequencing study⁵⁵ 2015 resequencing study
Pirim et al. Metabolism 2015; 602 non-Hispanic whites and 353 African blacks confirmed that rs1800775 independently associates with HDL-C in both European and African populations. Importantly, in Europeans this variant is in strong LD with TaqIB (rs708272, r²=0.75), but in African Americans LD is much weaker (r²=0.19) — meaning rs1800775 and TaqIB may capture largely overlapping signals in Europeans but distinct functional variation in Africans.

A meta-analytic evaluation⁶⁶ meta-analytic evaluation of 17 studies (5,441 CHD cases, 7,967 controls, 22,488 subjects in lipid analyses) found that the C allele associates with 3.65–4.36 mg/dL lower HDL-C and 0.45 μg/mL higher CETP mass. Among Caucasian populations, CC carriers had significantly higher CHD odds (OR 1.41–1.43 under dominant/homozygous models), while overall association in mixed populations was not significant — consistent with population heterogeneity in LD structure.

The HDL-C Paradox

A critical nuance: CETP variants that raise HDL by reducing cholesteryl ester transfer do not always translate into the same cardiovascular protection as HDL raised by other means. The HDL-raising effect of the -629A allele is partly attenuated by elevated triglycerides⁷⁷ partly attenuated by elevated triglycerides
When TG-rich lipoproteins are high, CETP transfer activity from HDL becomes dominated by mass-action effects of the TG substrate; CETP genotype effects on HDL diminish in high-TG states. The interaction between CETP genotype and plasma triglycerides means that the -629A benefit on HDL is largest at low triglyceride levels.

Practical Actions

For CC homozygotes, CETP expression is at its highest reference level, and HDL-C tends to run 3–6 mg/dL lower than in AA homozygotes. This is a modest but consistent effect operating as a background risk factor for low HDL. Lifestyle-level intervention can offset the genotype: aerobic exercise is one of the most robust HDL-raising stimuli and works regardless of CETP genotype. Dietary fat quality (replacing saturated fat with unsaturated fat) also supports HDL levels. The clinical priority for CC individuals is ensuring HDL-C is monitored regularly and that other lipid risk factors (LDL, triglycerides) are well managed, since the genotype alone does not cause disease.

For CA heterozygotes, HDL-C is in the population range but slightly elevated relative to CC individuals. No specific intervention is required.

For AA homozygotes, lower CETP activity raises HDL-C. Monitoring the full lipid panel rather than HDL alone is worthwhile: if HDL is elevated alongside high triglycerides, the cardiovascular benefit is reduced.

Interactions

rs1800775 is in strong LD with the CETP TaqIB variant rs708272 in European populations (r²=0.75). Tests that report TaqIB are largely capturing the same signal in Europeans, though rs1800775 is considered the functional variant given its direct transcriptional effect. In African ancestry populations, the two SNPs are only weakly correlated (r²=0.19), and both should be assessed independently.

CETP variants interact additively with LIPC variants (rs1532085) in raising HDL-C, but studies suggest the CETP-side interaction is what primarily translates to cardiovascular benefit. For individuals carrying CETP CC and LIPC GG genotypes, HDL may be at its lowest for both loci and monitoring is most important.

Interleukin-10 (IL-10) is the body's master anti-inflammatory cytokine¹¹ the body's master anti-inflammatory cytokine
IL-10 suppresses production of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β, acting as a critical brake on immune responses to prevent excessive inflammation. The IL10 gene on chromosome 1²² chromosome 1
Located at 1q31-32, position 206,773,062 encodes this regulatory cytokine. The -592 C>A polymorphism (rs1800872) sits in the promoter region, functioning as a dimmer switch that determines how much IL-10 your cells produce when inflammation begins. Unlike rs1800896 (IL10 -1082), which is already documented in GeneOps' immune-gut category, rs1800872 provides additional resolution on the IL-10 haplotype and captures distinct cardiovascular and metabolic inflammation angles.

The Mechanism

The -592 position is part of a highly polymorphic promoter region³³ highly polymorphic promoter region
The three main IL10 promoter SNPs (-1082, -819, -592) exhibit strong linkage disequilibrium and form distinct haplotypes that forms three predominant haplotypes controlling IL-10 transcription: GCC (high producer), ACC (intermediate), and ATA (low producer). The A allele at -592 is a component of the ATA haplotype⁴⁴ ATA haplotype
Associated with 2-4 fold reduction in IL-10 transcription, which causes considerably reduced promoter function and decreased IL-10 gene expression. The C-to-A exchange at position -592 disrupts transcription factor binding⁵⁵ disrupts transcription factor binding
Affects binding sites that regulate how actively the gene is transcribed into mRNA, leading to lower IL-10 production in response to inflammatory stimuli.

The functional impact creates a paradoxical situation: higher IL-10 production generally suppresses inflammation⁶⁶ higher IL-10 production generally suppresses inflammation
IL-10 downregulates synthesis of IL-1, IL-6, and TNF-α, which should be protective. However, in cardiovascular contexts, the AA genotype (low IL-10 producer) shows mixed associations—in some studies linked with increased atherosclerosis and coronary artery disease risk⁷⁷ increased atherosclerosis and coronary artery disease risk
Chinese population study found A allele associated with CAD, OR varies by population, yet paradoxically also associated with elevated HDL cholesterol, reduced intima-media thickness, and less peripheral artery stenosis⁸⁸ elevated HDL cholesterol, reduced intima-media thickness, and less peripheral artery stenosis
Russian study of acute coronary syndrome patients in certain populations. This complexity reflects IL-10's dual role: too little allows unchecked inflammation, but chronic elevation can signal uncontrolled inflammatory disease.

The Evidence

Cancer protection⁹⁹ Cancer protection
Meta-analysis of 70 studies encompassing 16,785 cases and 19,713 controls provides the strongest evidence: the AA genotype confers moderately decreased cancer risk (OR 0.90, 95% CI 0.83-0.98) compared to CC. The protective effect is particularly strong in smoking-related cancers (OR 0.77) and Asian populations (OR 0.79)¹⁰¹⁰ smoking-related cancers (OR 0.77) and Asian populations (OR 0.79). The mechanism likely involves the balance between anti-tumor immunity (requires some inflammation to clear cancer cells) versus chronic inflammation (which promotes tumorigenesis). Lower IL-10 production in AA carriers may allow more effective immune surveillance of pre-malignant cells.

Cardiovascular associations are more nuanced. A Chinese case-control study¹¹¹¹ Chinese case-control study
326 CAD patients vs. 248 controls found the A allele associated with increased coronary artery disease risk, with AA genotype carriers showing higher risk of >50% stenosis. Yet a Russian study¹²¹² Russian study
220 acute coronary syndrome patients found AA genotype carriers had elevated HDL cholesterol, reduced carotid intima-media thickness, lower frequency of peripheral artery stenosis, and—critically—increased IL-10 production despite the functional data suggesting the opposite. This paradox may reflect compensatory upregulation in the setting of active disease or population-specific genetic backgrounds.

The type 2 diabetes association is clearer. A North Indian study¹³¹³ North Indian study
260 T2DM patients vs. 280 controls found diabetes patients carried significantly more A alleles at -592 (25.6% vs. controls, P < 0.001). The mechanism involves chronic low-grade inflammation¹⁴¹⁴ mechanism involves chronic low-grade inflammation
Low serum IL-10 associated with increased T2DM and metabolic syndrome susceptibility—insufficient IL-10 allows persistent activation of inflammatory pathways that drive insulin resistance. Genotype-specific analysis showed CC genotype associated with T2DM¹⁵¹⁵ CC genotype associated with T2DM
Contrasting with AA's association with elevated HDL, while AA genotype paradoxically linked to both increased HDL and increased IL-10 in some cohorts.

In systemic lupus erythematosus¹⁶¹⁶ systemic lupus erythematosus
Iranian population study of 70 SLE patients vs. 211 controls, IL10 promoter polymorphisms including rs1800872 showed haplotype-dependent associations with disease activity and IL-10 levels. The complexity reflects IL-10's context-dependent effects: protective against inflammatory damage, yet high levels may indicate failure to resolve inflammation.

COVID-19 severity studies¹⁷¹⁷ COVID-19 severity studies
Brazilian and Egyptian cohort studies demonstrated that IL10 haplotypes (including -592) influence infection severity, with GCC haplotype homozygosity (high IL-10 producer) independently associated with severe disease (OR 2.77), possibly through excessive immunosuppression preventing viral clearance.

Practical Implications

Your genotype at -592 influences your baseline inflammatory regulation and may modulate risk for conditions ranging from cardiovascular disease to cancer to metabolic syndrome. The evidence suggests that IL-10 production exists in a Goldilocks zone—too little permits unchecked inflammation (atherosclerosis, insulin resistance), while chronic elevation signals inflammatory disease burden.

For cardiovascular health, the A allele shows population-specific and context-dependent effects. In some Asian populations it associates with increased CAD risk; in Eastern European populations with protective lipid profiles. The key insight: IL-10 is a marker of inflammatory tone, not a standalone risk factor. If you carry AA or AC genotypes, focus on anti-inflammatory dietary patterns¹⁸¹⁸ anti-inflammatory dietary patterns
Mediterranean diet consistently shows reductions in inflammatory markers including increased IL-10 rather than trying to "boost IL-10" in isolation.

For cancer risk, AA carriers show modest protection, particularly for smoking-related cancers. This isn't actionable in the sense of changing your genotype, but it underscores the importance of avoiding tobacco—the protective effect is stronger in smoking-exposed populations, suggesting lower IL-10 production may help clear pre-malignant cells in high-exposure settings.

For metabolic health, lower IL-10 production (AA genotype) may increase vulnerability to insulin resistance through chronic inflammatory signaling. Interventions that boost IL-10¹⁹¹⁹ Interventions that boost IL-10
Curcumin, omega-3s, Mediterranean diet, and mind-body practices increase IL-10 include omega-3 fatty acids (EPA/DHA), curcumin supplementation, vitamin D optimization, and mind-body practices like meditation that have been shown to increase IL-10 while reducing pro-inflammatory cytokines²⁰²⁰ increase IL-10 while reducing pro-inflammatory cytokines
Mindfulness retreat study showed significant IL-10 increases and IL-6/IL-8 reductions.

Interactions

The -592 variant (rs1800872) works in concert with two other IL10 promoter SNPs: -1082 A>G (rs1800896)²¹²¹ -1082 A>G (rs1800896)
Already documented in GeneOps' immune-gut category and -819 C>T (rs1800871). These three variants exhibit strong linkage disequilibrium²²²² strong linkage disequilibrium
They travel together on chromosomes forming specific haplotype blocks and form haplotypes that determine IL-10 production capacity:

• GCC haplotype (high IL-10 producer): -1082G / -819C / -592C — associated with elevated IL-10 secretion, which generally suppresses inflammation but in COVID-19 studies linked to severe disease²³²³ linked to severe disease
  GCC homozygosity OR 2.77 for severe COVID, possibly through excessive immunosuppression

• ATA haplotype (low IL-10 producer): -1082A / -819T / -592A — associated with 2-4 fold reduced IL-10 transcription, linked to increased inflammatory disease susceptibility²⁴²⁴ linked to increased inflammatory disease susceptibility
  Low IL-10 producer haplotype in multiple autoimmune and inflammatory conditions but potential cancer protection

• ACC haplotype (intermediate): -1082A / -819C / -592C — intermediate IL-10 production

Understanding your full IL-10 haplotype requires knowing all three positions. If you're AA at -592, you likely carry at least one copy of the low-producer ATA haplotype, particularly if you also carry AA at -1082 (rs1800896). The combined effect is stronger than either variant alone—haplotype analysis in Iranian SLE patients²⁵²⁵ Iranian SLE patients
Study of 70 patients vs. 211 controls showed haplotype associations with disease activity that weren't apparent from single-SNP analysis.

The interaction with environmental factors is critical. Mindfulness and stress reduction interventions²⁶²⁶ Mindfulness and stress reduction interventions
Meta-analysis of mind-body interventions across multiple inflammatory diseases significantly increase IL-10 production, potentially compensating for genetically low expression. Similarly, omega-3 supplementation²⁷²⁷ omega-3 supplementation
EPA specifically lowers TNF-α/IL-10 ratio and dietary patterns like the Mediterranean diet combined with curcumin²⁸²⁸ Mediterranean diet combined with curcumin
RCT in ulcerative colitis patients show synergistic effects on inflammatory markers including IL-10.

Deep inside every cell, mitochondria must replicate their own small genome — a 16,569 base pair circle of DNA encoding 13 essential proteins of the electron transport chain. This task falls to TFAM (Transcription Factor A, Mitochondrial), a compact protein that wraps around mitochondrial DNA, initiates its transcription, and oversees its replication and repair. Without adequate TFAM activity, mitochondria lose the capacity to maintain their genome, energy production falters, and the accelerated mitochondrial DNA deletions and mutations that characterize aging accumulate faster.

The rs1937 variant (+35G>C in exon 1) sits in a particularly sensitive position: codon 12 of TFAM, within the mitochondrial targeting sequence that guides the nascent protein into the mitochondrion. The common G allele encodes serine at position 12 (S12), while the rarer C allele encodes threonine (T12). This conservative amino acid swap — both serine and threonine are small polar residues — nonetheless affects TFAM function in ways that appear to matter across the lifespan.

The Mechanism

The Ser12Thr substitution sits in the N-terminal mitochondrial targeting sequence (MTS), the signal peptide that is cleaved after import into the mitochondrion. Although this signal peptide does not become part of the mature TFAM protein, its amino acid composition influences the efficiency and fidelity of mitochondrial import. The Thr12 (C allele) variant may alter the hydrophobicity or secondary structure of the MTS in ways that affect import kinetics, or may influence co-translational regulation of the full-length precursor.

TFAM is a direct transcriptional target of NRF1, placing it downstream in the canonical mitochondrial biogenesis cascade: exercise and nutrient stress activate PGC-1α → PGC-1α co-activates NRF1 → NRF1 drives TFAM expression → TFAM enters mitochondria to replicate mtDNA and drive transcription of electron transport chain subunits. Variation at rs1937 therefore sits at the endpoint of a pathway already shaped by NRF1 variants rs6949152 and rs2402970, both of which are in the GeneOps database.

Mitochondrial function decline is one of the nine hallmarks of aging. TFAM abundance is reduced in aged tissues and in Alzheimer's disease brains; restoring TFAM in animal models has extended lifespan and reduced neurodegeneration. The rs1937 C allele appears to preserve mitochondrial function in aging in ways the common G allele does not fully replicate.

The Evidence

The clearest longevity signal comes from two independent case-control cohorts on different continents. In a Spanish centenarian cohort¹¹ In a Spanish centenarian cohort
Santiago et al. Mitochondriogenesis genes and extreme longevity. Rejuvenation Res. 2013 examining 107 centenarians against 284 young adults, the CC genotype appeared exclusively in the centenarian group — 2.8% of centenarians carried it, while it was absent in controls entirely (p=0.003). The effect was striking given the study's modest size.

The more powered replication comes from China. The CLHLS cohort study²² The CLHLS cohort study
Zhu et al. Association between SNP of rs1937 in TFAM and longevity among the elderly Chinese. BMC Geriatrics. 2022 compared 1,907 long-lived individuals (≥90 years) against 1,387 young elderly (65–74 years) and found the CC genotype associated with longevity (OR 1.989, 95% CI 1.160–3.411, p=0.003). The C-allele frequency was 16.9% in long-lived participants vs 14.2% in younger controls, a modest but statistically significant enrichment. The association strengthened among those not living alone, suggesting social engagement may amplify or moderate the genetic effect.

Evidence for the G allele as a risk factor spans Alzheimer's disease research as well. A Spanish AD cohort³³ A Spanish AD cohort
Gómez-Durán et al. TFAM gene variation and risk of late-onset Alzheimer's disease. J Alzheimers Dis. 2008 found GG homozygosity significantly more frequent in 300 LOAD patients than in 183 healthy controls (92% vs 86%, OR 1.91, p=0.04). A German study⁴⁴ A German study
Günther et al. Possible association of TFAM genotype with sporadic Alzheimer disease. Neurosci Lett. 2004 of 372 AD patients and 295 controls identified a TFAM haplotype carrying the rs1937 G allele as a moderate risk factor, particularly in women. And a Norwegian cognitive study⁵⁵ a Norwegian cognitive study
Bøttger et al. TFAM rs1937 and APE1 rs1130409 alleles associated with reduced cognitive performance. Neurosci Lett. 2017 found G-allele carriers showed reduced MMSE scores across AD patients, patient controls, and healthy controls.

It should be noted that one Han Chinese study found the C allele protective against AD in that population — the evidence is consistent in direction (C protective, G risk) but the effect magnitudes and statistical confidence vary across cohorts, reflecting genuine biological heterogeneity and modest sample sizes.

The overall picture points to rs1937 as an emerging longevity-relevant variant with preliminary-to-moderate evidence: the C allele is enriched in long-lived individuals, and the G allele associates with cognitive decline and Alzheimer's risk. The evidence is not yet at the level of established longevity markers like FOXO3 rs2802292 or APOE, but the NRF1→TFAM biological axis is compelling and the two independent longevity associations strengthen the signal.

Practical Implications

For individuals carrying the GG genotype, lifestyle choices that maximize TFAM expression and mitochondrial function become especially important. Endurance and resistance exercise are the most potent natural inducers of the PGC-1α→NRF1→TFAM pathway — both have documented capacity to upregulate TFAM protein and mtDNA copy number in muscle and brain tissue. Caloric restriction and intermittent fasting activate the same cascade through AMPK and SIRT1 signaling.

Mitochondria-targeted antioxidant strategies may also be relevant. Coenzyme Q10 and MitoQ (mitochondria-targeted ubiquinone) support electron transport chain efficiency and reduce mitochondrial ROS production — the primary driver of mtDNA damage that TFAM must continuously repair. Reducing chronic inflammation through diet and lifestyle reduces the oxidative burden on mitochondrial DNA.

Cognitive monitoring deserves attention for GG carriers given the Alzheimer's association data, particularly those with a family history of neurodegenerative disease. Aerobic exercise has the strongest evidence base for maintaining mitochondrial function in the brain and reducing AD risk independent of genetics.

Interactions

rs1937 sits at the bottom of the NRF1→TFAM axis. Individuals carrying risk variants in both upstream regulators — NRF1 rs6949152 (G allele) and NRF1 rs2402970 — and the downstream rs1937 G allele may have compounded reductions in mitochondrial biogenesis capacity. The upstream regulator PPARGC1A rs8192678 (the PGC-1α Gly482Ser variant) further shapes this pathway; carriers of the Ser allele show reduced PGC-1α activity, which would amplify any downstream TFAM insufficiency.

The broader longevity context places rs1937 alongside FOXO3 rs2802292: both are downstream effectors of cellular stress-resistance pathways, both show their most consistent effects in oxidative-stress and energy-metabolism biology, and both point toward exercise and hormetic interventions as the actionable mitigation strategy.

The human body runs on fat during sustained exercise and fasting — but getting fatty acids into mitochondria requires a molecular ferry service. CPT2 (carnitine palmitoyltransferase II) is the enzyme that completes this ferry crossing, releasing long-chain acyl groups into the mitochondrial matrix for beta-oxidation. When CPT2 fails, fatty acids accumulate outside mitochondria, cells starve of energy, and skeletal muscle breaks down¹¹ skeletal muscle breaks down
rhabdomyolysis: the dissolution of muscle fiber contents including myoglobin, potassium, and creatine kinase into the bloodstream.

rs201065226 is an ultra-rare stop-gain variant in CPT2: the T allele substitutes a premature stop codon (p.Arg124Ter) at amino acid 124, truncating the 658-amino-acid protein before it can fold into its active form. With no functional CPT2 protein produced from this allele, carriers depend entirely on the one working copy; individuals inheriting two T alleles have no enzyme activity at all.

The Mechanism

CPT2 sits on the inner mitochondrial membrane and works in tandem with CPT1 on the outer membrane. CPT1 attaches a carnitine group to long-chain acyl-CoA (forming acylcarnitine), which crosses into the matrix; CPT2 then reverses this reaction, regenerating acyl-CoA for oxidation and releasing free carnitine to be recycled. The p.Arg124Ter truncation eliminates all of CPT2's catalytic domain. Without CPT2, acylcarnitines accumulate in plasma, free carnitine falls, and muscles must shift entirely to glucose and short-chain fuels — a supply that is rapidly exhausted during prolonged exercise or caloric restriction.

CPT2 is also extremely thermoliable²² extremely thermoliable
the enzyme loses activity faster than normal at elevated body temperatures, which is why fever and vigorous exercise in heat disproportionately trigger crises even in heterozygous carriers.

The Evidence

ClinVar classifies the T allele of rs201065226 as Pathogenic across multiple submissions (RCV000185829 and related records), associated with CPT2 deficiency in its severe infantile, lethal neonatal, and myopathic forms, as well as susceptibility to infection-induced acute encephalopathy. The T allele frequency is approximately 1 in 148,768 chromosomes in gnomAD genomes v4 — one observed heterozygote across the entire database — confirming extreme rarity and high penetrance.

Anichini et al. 2011³³ Anichini et al. 2011
Neurol Res cohort of 25 biochemically confirmed CPT2-deficient patients documented that individuals with null mutations (stop codons, frameshifts) or homozygous missense mutations showed more pronounced reductions in enzyme activity and more severe phenotypes. Critically, the study identified symptomatic obligate heterozygotes, confirming that a single loss-of-function allele can manifest clinically when combined with environmental stressors or additional modifying factors.

Vladutiu et al. 2000⁴⁴ Vladutiu et al. 2000
Mol Genet Metab documented CPT2 enzyme activity reduced to 13–47% of normal in heterozygous carriers across different tissues. Triggers for symptomatic episodes included prolonged exercise, fasting, viral infection, anesthesia, and temperature extremes — the same constellation that characterizes the adult myopathic form.

For treatment, Bonnefont et al. 2010⁵⁵ Bonnefont et al. 2010
Clin Pharmacol Ther, n=6 demonstrated that bezafibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, increased palmitoyl-CoA oxidation rates by 39–206% (P=0.028) in myopathic CPT2 patients and significantly improved physical activity capacity and quality of life over a 3-year follow-up. Djouadi et al. 2006⁶⁶ Djouadi et al. 2006 showed the mechanism: fibrates upregulate residual CPT2 enzyme activity in patient-derived fibroblasts. Medium-chain triglycerides (MCT oil) bypass the CPT1/CPT2 transport system entirely, providing an alternative mitochondrial fuel during exercise.

Practical Actions

Heterozygous T carriers should structure exercise to avoid prolonged aerobic work that drains glycogen stores and forces heavy reliance on long-chain fat oxidation. Avoid exercising in the fasted state. Keep a fast-acting carbohydrate source available during endurance activity and shift toward carbohydrate-dominant fueling strategies for sessions exceeding 60–90 minutes. Fasting beyond 12–14 hours should be avoided or carefully supervised.

Any illness with fever should prompt reduced physical activity — the combination of CPT2's thermoliability and illness-driven metabolic stress is a recognized rhabdomyolysis trigger. Dark urine (myoglobinuria) after intense exercise or illness is an emergency requiring immediate hospital evaluation and aggressive IV hydration.

Adding MCT oil to the diet provides medium-chain fatty acids (8–12 carbons) that reach mitochondria without CPT2, supplementing fuel availability during fat-burning demand. L-carnitine supplementation may help maintain free carnitine levels, which fall when acylcarnitines accumulate. Bezafibrate is the best-evidenced pharmacological option for the myopathic form, though it requires a clinician's prescription.

Interactions

The most common pathogenic CPT2 variant worldwide is p.Ser113Leu (rs74315294). Individuals who are compound heterozygous for one p.Ser113Leu allele and one p.Arg124Ter allele (like rs201065226) carry zero functional CPT2 copies and typically present with the severe myopathic or infantile form, with near-zero residual enzyme activity. This compound heterozygous combination is the most clinically relevant scenario for rs201065226 T carriers, since inheriting two T alleles of this ultra-rare variant is essentially impossible in the general population. Genetic testing for the full CPT2 coding region — especially p.Ser113Leu — should accompany any rs201065226 T result to assess compound heterozygosity.

Mitral valve prolapse (MVP) affects approximately 1 in 40 people globally, making it the most common heart valve abnormality — yet for decades its molecular causes were largely unknown. DCHS1 (Dachsous Cadherin-Related 1) encodes a protocadherin that functions as an intercellular signal in the planar cell polarity (PCP) pathway¹¹ planar cell polarity (PCP) pathway
A signaling system that coordinates the orientation and movement of cells within a tissue plane during organ development, and its product is essential for the proper morphogenesis of heart valves. The rs201457110 variant introduces an arginine-to-histidine change at position 2513 of the DCHS1 protein, destabilizing the protein and disrupting the cellular architecture of the developing mitral valve.

This is a rare pathogenic variant — the T allele is carried by roughly 1 in 4,000 people globally, though the frequency is considerably higher in East Asian populations (~1 in 300). The variant is autosomal dominant: a single copy of the T allele is sufficient to cause valve disease in affected family members.

The Mechanism

DCHS1 operates as part of the DCHS1–FAT4 signaling axis²² DCHS1–FAT4 signaling axis
FAT4 is the binding partner of DCHS1; together they transmit planar polarity signals from cell to cell during organogenesis, controlling how cells orient themselves and migrate during organ formation. In the developing heart, this pathway is required for normal mitral leaflet morphogenesis — shaping the thin, pliable leaflets that prevent blood from flowing backward from the left ventricle into the atrium during each heartbeat.

The R2513H variant does not impair mRNA production; instead, it dramatically accelerates protein degradation. In transfected cell models, the mutant DCHS1 protein was reduced by approximately 60% compared to wild-type, with the protein's half-life falling from 5.8 hours to just 1.6 hours — the hallmark of a loss-of-function destabilization mechanism³³ loss-of-function destabilization mechanism
The protein is made normally but is degraded too rapidly, so less of it is available for intercellular signaling. This reduced DCHS1 dosage impairs the coordinated cell migration and polarity signals that sculpt the mitral leaflets during fetal development, leading to myxomatous thickening and elongation of the leaflets that physically prolapse into the left atrium during systole.

The Evidence

The variant was first identified by Durst et al. (Nature, 2015)⁴⁴ Durst et al. (Nature, 2015)
50-author multi-center collaboration; identified DCHS1 mutations in three families with familial MVP through linkage analysis and exome sequencing of a five-generation family. The R2513H mutation co-segregated with MVP in all tested family members, was absent from 4,300 European-American controls in the NHLBI Exome Sequencing Project, and failed to rescue zebrafish atrioventricular canal defects that wild-type DCHS1 mRNA fully corrected — establishing pathogenicity beyond segregation alone. A parallel mouse model (Dchs1+/− heterozygous knockouts) spontaneously developed mitral valve prolapse with a characteristically elongated posterior leaflet, directly mirroring the human disease phenotype.

The broader clinical significance of DCHS1 variants was extended by Clemenceau et al. (2018)⁵⁵ Clemenceau et al. (2018)
Sequencing all 21 DCHS1 exons in 100 unrelated patients with moderate-to-severe mitral regurgitation, who found that 24 out of 100 sporadic MVP cases carried at least one predicted-deleterious DCHS1 missense variant, suggesting DCHS1 accounts for a substantial fraction of apparently sporadic MVP. A minority of studies in primarily sporadic cohorts have found lower rates, underscoring that DCHS1 is one of several MVP genes rather than a singular universal cause.

The variant is classified as Pathogenic in ClinVar (VCV000217870) for the condition "Mitral valve prolapse, myxomatous 2" (OMIM 607829), based on the family segregation and functional evidence.

Practical Actions

MVP caused by DCHS1 mutations ranges from clinically silent leaflet thickening to hemodynamically significant mitral regurgitation requiring surgical repair. Importantly, a subset of MVP patients — particularly those with bileaflet involvement, mitral annular disjunction, or complex ventricular ectopy — faces elevated risk of ventricular arrhythmia and sudden cardiac death⁶⁶ ventricular arrhythmia and sudden cardiac death
Studies of arrhythmogenic MVP identify papillary muscle fibrosis and myocardial stretch as the substrate for life-threatening arrhythmias in susceptible individuals.

For T allele carriers, the priority is cardiology evaluation to establish baseline mitral valve anatomy and function. Echocardiography is the definitive diagnostic and surveillance tool. Asymptomatic individuals with minimal or no mitral regurgitation on baseline echo can typically be followed every 3–5 years; those with significant regurgitation or high-risk features (bileaflet prolapse, biphasic T waves in inferior leads, frequent premature ventricular contractions) require closer monitoring including 24-hour Holter recording. First-degree relatives of affected individuals should also be offered echocardiographic screening.

Interactions

DCHS1 functions as the ligand for FAT4 in the planar cell polarity pathway. Other genes in the MVP genetic architecture include FLNA (X-linked filamin A, causing X-linked MVP), DZIP1, and PLD1. DCHS1 mutations act in isolation as an autosomal dominant monogenic cause of MVP; no specific gene-gene interactions at the variant level have been characterized, but the shared DCHS1–FAT4 signaling axis means that FAT4 variants may theoretically modify expressivity.

Chromosome 1q22 is one of the most consistently replicated gastric cancer susceptibility regions in the human genome. rs2075570 is an intronic variant¹¹ intronic variant
Located within intron 2 of MTX1 (metaxin 1), about 50 kb from MUC1's transcription start site that serves as a tag SNP for this locus — a marker in tight linkage disequilibrium²² linkage disequilibrium
Linkage disequilibrium means two variants are co-inherited so frequently that knowing one predicts the other with functional variants that directly regulate the expression of genes critical for gastric mucosal defense. It was co-identified with rs2070803 in the first gastric cancer genome-wide association study performed in a Japanese population and has since been replicated across Chinese, Korean, and other East Asian cohorts.

The Mechanism

rs2075570 itself does not change any protein sequence — it is an intronic variant in MTX1 with no direct functional consequence. Its significance lies in what it tags. Fine-mapping of the 64.8 kb high-LD block containing rs2075570 identified two functional germline enhancer variants³³ germline enhancer variants
Germline variants present in every cell from birth, inherited from parents — rs2049805-C and rs2974931-G — that reside in an active chromatin region. These variants strengthen enhancer activity, which in turn upregulates the expression of UBAP2L (ubiquitin-associated protein 2-like)⁴⁴ UBAP2L (ubiquitin-associated protein 2-like)
UBAP2L promotes cell proliferation and invasion; its overexpression in gastric cancer tissue correlates with worse patient survival over a remarkable 960 kb chromatin loop distance. The 1q22 block simultaneously encompasses MUC1⁵⁵ MUC1
Mucin-1 protects the gastric epithelium by blocking H. pylori adhesion and maintaining mucus barrier integrity, whose own functional variant rs4072037 operates through a distinct splicing mechanism — meaning rs2075570 marks a region where at least two independent biological pathways converge to shape gastric cancer risk.

The Evidence

The original Japanese GWAS identified the 1q22 region defined by rs2075570 and rs2070803 at P~1×10⁻⁷. Meta-analysis of Japanese and Korean populations⁶⁶ Meta-analysis of Japanese and Korean populations
Saeki et al., Gastroenterology 2011; confirmed across multiple East Asian cohorts yielded OR=1.71 (P=2.3×10⁻¹²) for gastric cancer, placing this among the strongest common-variant associations for this malignancy. A field synopsis and meta-analysis⁷⁷ field synopsis and meta-analysis
Mocellin et al., Gut 2015, the most comprehensive systematic review of gastric cancer susceptibility variants rated rs2075570 as one of 11 high-evidence biomarkers — the highest tier based on multiple large replicated studies. The association is specific to diffuse-type gastric cancer⁸⁸ diffuse-type gastric cancer
Diffuse gastric cancer is the more aggressive subtype, often presenting at advanced stage and lacking the intestinal precursor lesions that permit earlier detection, not intestinal-type, suggesting the underlying pathway relates to mucosal barrier integrity and submucosal invasion rather than to gastric acid secretion and intestinal metaplasia. A survival analysis of GC cases at high-evidence susceptibility loci has been conducted, though the specific prognostic role of rs2075570 independently requires further study — the incidence and prognosis associations do not always track together in cancer genetics.

Practical Implications

The T allele is the common allele in most populations (52% globally, 80% in East Asians), and carrying one or two copies of T is associated with modestly elevated gastric cancer risk compared to CC homozygotes. The risk is best understood as a population-level susceptibility signal — it does not imply inevitable disease but indicates that normal mucosal defense and barrier genes in the 1q22 region are functioning at a genetically reduced baseline in T carriers. Given the clear gene-environment interaction at this locus, H. pylori infection dramatically amplifies risk for any genetic background at 1q22. Testing for and treating H. pylori remains the highest-yield intervention for T carriers.

The finding that enhanced UBAP2L expression promotes gastric cancer cell proliferation and invasion connects this variant to a druggable axis — UBAP2L inhibition has been shown to suppress gastric cancer cell growth in preclinical models, though no clinical applications exist yet.

Interactions

rs2075570 is in the same 724 kb LD block as rs4072037 (MUC1 synonymous variant, splicing effect) and rs2070803 (MUC1 intergenic variant). While they are correlated, rs4072037 operates through MUC1 alternative splicing — a distinct mechanism from the UBAP2L enhancer pathway tagged by rs2075570. Carriers of risk variants at both rs4072037 and rs2075570 may experience compounding effects on gastric mucosal vulnerability through two independent biological routes: reduced MUC1 mucus barrier effectiveness (rs4072037) and enhanced pro-proliferative gene expression via UBAP2L (rs2075570). H. pylori infection interacts with both pathways and represents the dominant modifiable risk factor.